Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

National, Multicenter, Non-interventional, Prospective Study to Explore the Quality of Life of Patients With Severe Asthma Starting Treatment With Dupilumab (Dupixent) in a Real-world Setting

Next Previous
Trial Profile

National, Multicenter, Non-interventional, Prospective Study to Explore the Quality of Life of Patients With Severe Asthma Starting Treatment With Dupilumab (Dupixent) in a Real-world Setting

Status: Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 27 Nov 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dupilumab (Primary)
  • Indications Asthma
  • Focus Therapeutic Use
  • Acronyms PROVERB
  • Sponsors Sanofi

Most Recent Events

  • 25 Nov 2024 Status changed from recruiting to active, no longer recruiting.
  • 09 Apr 2024 Planned End Date changed from 18 Sep 2025 to 3 Oct 2025.
  • 09 Apr 2024 Planned primary completion date changed from 8 Sep 2025 to 3 Oct 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top